Adaptive designs for IVPT data with mixed scaled average bioequivalence.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 1116, doi. 10.1002/pst.2333
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2023 AND VI 22 AND IP 6
Results: 13
1
2
A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 1104, doi. 10.1002/pst.2332
- By:
- Publication type:
- Article
3
Adaptive designs for best treatment identification with top‐two Thompson sampling and acceleration.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 1089, doi. 10.1002/pst.2331
- By:
- Publication type:
- Article
4
Calculation of Phase 2 dose‐finding study sample size for reliable Phase 3 dose selection.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 1076, doi. 10.1002/pst.2330
- By:
- Publication type:
- Article
5
"Super‐covariates": Using predicted control group outcome as a covariate in randomized clinical trials.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 1062, doi. 10.1002/pst.2329
- By:
- Publication type:
- Article
6
Inclusion of binary proxy variables in logistic regression improves treatment effect estimation in observational studies in the presence of binary unmeasured confounding variables.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 995, doi. 10.1002/pst.2323
- By:
- Publication type:
- Article
7
Information fraction estimation: Strategies for a phase 3 non‐inferiority maximum duration design with time to event outcome.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 1031, doi. 10.1002/pst.2327
- By:
- Publication type:
- Article
8
Adherence, per‐protocol effects, and the estimands framework.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 1141, doi. 10.1002/pst.2326
- By:
- Publication type:
- Article
9
Leading beyond regulatory approval: Opportunities for statisticians to optimize evidence generation and impact clinical practice.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 1135, doi. 10.1002/pst.2325
- By:
- Publication type:
- Article
10
Two‐sample inference procedures under nonproportional hazards.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 1016, doi. 10.1002/pst.2324
- By:
- Publication type:
- Article
11
Type‐I‐error rate inflation in mixed models for repeated measures caused by ambiguous or incomplete model specifications.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 1046, doi. 10.1002/pst.2328
- By:
- Publication type:
- Article
12
Modeling immunogenecity data to establish screening bioassays cut point.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 978, doi. 10.1002/pst.2322
- By:
- Publication type:
- Article
13
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 6, p. 975, doi. 10.1002/pst.2240
- Publication type:
- Article